Key facts
- This page summarizes Robert Michael Dudley's Form 4 filing for Transcode Therapeutics, Inc. (RNAZ).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Oct 2023, 16:37.
Robert Michael Dudley - 28 Sep 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- RNAZ
- Reported as of
- 28 Sep 2023
- Net transaction value
- +$49,980
- SEC form
- 4
- Accepted by SEC
- 02 Oct 2023, 16:37:49 UTC
- Prior SEC filing
- 22 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas A. Fitzgerald, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Michael Dudley filed Form 4 for Transcode Therapeutics, Inc. (RNAZ) on 02 Oct 2023.
Change
- Previous filing in this sequence was filed on 22 Jun 2023.
- Current net transaction value: +$49,980.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RNAZ
transaction
Common Stock
Purchase
- Transaction value
- $49,980
- Shares
- +98,000
- Change %
- +119%
- Price
- $0.5100
- Shares after
- 180,262
- Date
- 28 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer.